Catalyst OrthoScience Closes $12.7 Million Series C-1 Private Financing

England Securities recently served as the exclusive placement agent to Catalyst OrthoScience Inc. (Catalyst) in its $12.7 million oversubscribed Series C-1 financing round led by River Cities Capital Funds (River Cities).

England Securities recently served as the exclusive placement agent to Catalyst OrthoScience Inc. (Catalyst) in its $12.7 million oversubscribed Series C-1 financing round led by River Cities Capital Funds (River Cities).

Catalyst develops and markets a disruptive technology that represents the next evolution in shoulder surgery. Its shoulder replacement system is the only one that incorporates an innovative elliptical humeral head design that matches the human anatomy. Further, its simple surgical technique minimizes bone removal to preserve the strongest bone for implant fixation and employs patented angled instruments to minimize procedure invasiveness. The precision of the system yields highly accurate and repeatable restoration of the natural anatomy.

The funding will allow Catalyst to increase its inventory, expand its distribution networks and marketing efforts, and develop new product components. The Catalyst CSR™ Total Shoulder System has been used in more than 1,000 surgeries. First patients are more than two years post surgery with excellent clinical results.

Brian K. Hutchison, Chairman and Chief Executive Officer of Catalyst, stated "England's  healthcare investment banking team was instrumental in securing an ideal lead investor with  relevant orthopedic extremity experience and focus on companies of our stage. The team also  helped us navigate through some unique challenges and demonstrated structural creativity to  help us achieve this exceptional outcome."

 

All transactions